TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1592965

Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste (1000 ppm F)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste (1500 ppm F)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-fluoride toothpaste
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Brushing frequency three times per day with fluoridated dentifrice
Number of subjects: 36

Group type: COMPARATOR
Intervention: Brushing frequency twice per day
Number of subjects: 36
Study: 27900649

Group type: EXPERIMENTAL
Intervention: Facilitated care (telephone-based intervention)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 100
Study: 27835711

Group type: EXPERIMENTAL
Intervention: 49-channel suprachoroidal-transretinal stimulation (STS) retinal prosthesis
Number of subjects: 3

Group type: COMPARATOR
Intervention: Prosthesis turned off
Number of subjects: 3
Study: 24591201

Group type: EXPERIMENTAL
Intervention: Bendamustine plus rituximab (BR)
Number of subjects: 447

Group type: COMPARATOR
Intervention: R-CHOP/R-CVP
Number of subjects: 447
Study: 23837551

Group type: EXPERIMENTAL
Intervention: exposure_long (15 sessions)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: exposure_short (10 sessions)
Number of subjects: 108

Group type: COMPARATOR
Intervention: cognitive behavioral therapy (15 sessions)
Number of subjects: 108
Study: 20228986

Group type: EXPERIMENTAL
Intervention: G2 (placebo mouthwash)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: G3 (mouthwash with essential oils)
Number of subjects: 30

Group type: COMPARATOR
Intervention: G1 (control group with orientation regarding oral hygiene)
Number of subjects: 30
Study: 18544018

Group type: EXPERIMENTAL
Intervention: Antiretroviral drugs (ARVs)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 16185306

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 10 mg kg(‐1) die(‐1) for 30 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12663287

Group type: EXPERIMENTAL
Intervention: 10 mg Fe (Fe group)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: 10 mg Zn (Zn group)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: 10 mg Fe + 10 mg Zn (Fe+Zn group)
Number of subjects: 680

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 680
Study: 11573726

Group type: EXPERIMENTAL
Intervention: Transcatheter arterial infusion with 5‐fluorouracil/doxorubicin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oily chemoembolization with doxorubicin‐in‐iodized oil and gelatin sponge
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Transcatheter arterial infusion
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oily chemoembolization
Number of subjects: 24
Study: 8659969

Group type: EXPERIMENTAL
Intervention: Computed tomography (CT)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Hepatic perfusion scintigraphy (HPI)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasound (US)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Static scintigraphy
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Dynamic scintigraphy (HPI)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasound (IOUS)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Manual palpation
Number of subjects: 73
Study: 1815225

Group type: EXPERIMENTAL
Intervention: 0.15 IU AVP
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.5 IU AVP
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.5 IU OX
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6383134

Group type: EXPERIMENTAL
Intervention: Interposed abdominal compression CPR (IAC-CPR)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 140
Study: 30915991

Group type: EXPERIMENTAL
Intervention: 15 mg PF‐06372865
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 65 mg PF‐06372865
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pregabalin (300 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30442588

Group type: EXPERIMENTAL
Intervention: Lobar resection
Number of subjects: 697

Group type: COMPARATOR
Intervention: Sublobar resection
Number of subjects: 697
Study: 27025186

Group type: EXPERIMENTAL
Intervention: Cediranib 20 mg once-daily alongside chemotherapy then cediranib 20 mg once-daily maintenance (arm C)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Placebo alongside chemotherapy then placebo only maintenance (arm A)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Cediranib 20 mg once-daily alongside chemotherapy then placebo only maintenance (arm B)
Number of subjects: 456
Study: 24696091

Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide (HU)
Number of subjects: 32
Study: 22853047

Group type: EXPERIMENTAL
Intervention: Warm handoff
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fax referral
Number of subjects: 0
Study: 20194414

Group type: EXPERIMENTAL
Intervention: Social recovery‐focused cognitive‐behavioral therapy (SRCBT)
Number of subjects: 77
Study: 16883918

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 0
Study: 12631309

Group type: EXPERIMENTAL
Intervention: Community-based Directly Observed Treatment (CBDOT)
Number of subjects: 522

Group type: COMPARATOR
Intervention: Institutional-based Directly Observed Treatment (IBDOT)
Number of subjects: 522
Study: 10839907

Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine and 0.5 microg/ml sufentanil
Number of subjects: 200

Group type: COMPARATOR
Intervention: 0.1% bupivacaine and 0.5 microg/ml sufentanil
Number of subjects: 200
Study: 9499512

Group type: EXPERIMENTAL
Intervention: Cemented hip prosthesis
Number of subjects: 60

Group type: COMPARATOR
Intervention: Noncemented hip prosthesis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cemented vs Noncemented
Number of subjects: 60
Study: 8258575

Group type: EXPERIMENTAL
Intervention: Resin composite restorations
Number of subjects: 244

Group type: COMPARATOR
Intervention: Amalgam restorations
Number of subjects: 244
Study: 3878906

Group type: EXPERIMENTAL
Intervention: Cellulose hydrate membrane
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate dialyzers
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cuprophan dialyzers
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ethylene‐vinyl alcohol copolymer dialyzers
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Polyacrylonitrile dialyzers
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Polyacrylonitrile and polymethylmethacrylate membranes
Number of subjects: 15
Study: 31374181

Group type: EXPERIMENTAL
Intervention: EMPOWER program (postintervention group)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Preintervention group (control)
Number of subjects: 38
Study: 28636854

Group type: EXPERIMENTAL
Intervention: Lying-flat position for 24 hours
Number of subjects: 11093

Group type: COMPARATOR
Intervention: Sitting-up position with head elevated to at least 30 degrees for 24 hours
Number of subjects: 11093
Study: 27295811

Group type: EXPERIMENTAL
Intervention: Combined aerobic exercise using treadmill and stretching exercises for 12 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 54
Study: 24116981

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided shunt insertion
Number of subjects: 121

Group type: COMPARATOR
Intervention: Conventional shunt insertion
Number of subjects: 121
Study: 21871706

Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg once daily
Number of subjects: 325

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study: 18534398

Group type: EXPERIMENTAL
Intervention: Lateral release during total knee arthroplasty
Number of subjects: 59

Group type: COMPARATOR
Intervention: Total knee arthroplasty without lateral release
Number of subjects: 59
Study: 17498388

Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride with 0.5 MHz ultrasound
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride with 1.0 MHz ultrasound
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride alone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 15282352

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus ribavirin
Number of subjects: 133

Group type: COMPARATOR
Intervention: Interferon alfa-2a plus ribavirin
Number of subjects: 133
Study: 12053678

Group type: EXPERIMENTAL
Intervention: Intracoronary radiotherapy with a prescribed dose of 17 Gy delivered via a Re‐188 filled balloon catheter.
Number of subjects: 34
Study: 9717676

Group type: EXPERIMENTAL
Intervention: WF10
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 7641968

Group type: EXPERIMENTAL
Intervention: Intravenous sulprostone after cervical priming with dinoprostone
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intramuscular sulprostone only
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous sulprostone only
Number of subjects: 100
Study: 2650590

Group type: EXPERIMENTAL
Intervention: Acoustic otoscopy
Number of subjects: 114

Group type: COMPARATOR
Intervention: Pneumatic otoscopy
Number of subjects: 114
Study: 905483

Group type: EXPERIMENTAL
Intervention: High tone (1500 Hz) at a priori probability levels
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low tone (1000 Hz) at a priori probability levels
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Task-relevant stimuli
Number of subjects: 10

Group type: COMPARATOR
Intervention: Alternate task (irrelevant tones)
Number of subjects: 10
Study: 31033335

Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Electroacupuncture
Number of subjects: 44
Study: 28981739

Group type: EXPERIMENTAL
Intervention: Pelvic and para-aortic lymphadenectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pelvic lymphadenectomy alone
Number of subjects: 0
Study: 25881883

Group type: EXPERIMENTAL
Intervention: Hysteroscopic endometrial ablation (HEA)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Laparoscopic supracervical hysterectomy (LSH)
Number of subjects: 153
Study: 23748162

Group type: EXPERIMENTAL
Intervention: Web-based program promoting nutrition and physical activity (Teen Choice: Food and Fitness)
Number of subjects: 408
Study: 21481708

Group type: EXPERIMENTAL
Intervention: Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 19595410

Group type: EXPERIMENTAL
Intervention: Unilateral manual stimulation of acupuncture points LU7 and KD6 (3 sessions)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Unilateral manual stimulation of acupuncture point LU7
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Unilateral manual stimulation of acupuncture point KD6
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no acupuncture treatment)
Number of subjects: 60
Study: 16960863

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 536

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 536
Study: 15312255

Group type: COMPARATOR
Intervention: sCT 1.0 mg (daily)
Number of subjects: 277

Group type: COMPARATOR
Intervention: sCT (various doses)
Number of subjects: 277
Study: 11340522

Group type: EXPERIMENTAL
Intervention: Poorly absorbable antifungal agents
Number of subjects: 3002

Group type: EXPERIMENTAL
Intervention: Absorbable antifungal agents
Number of subjects: 3002

Group type: COMPARATOR
Intervention: No antifungal prophylaxis
Number of subjects: 3002
Study: 9130130

Group type: EXPERIMENTAL
Intervention: Tricuspid annuloplasty (TAP) performed according to the modified De Vega technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-TAP (no tricuspid annuloplasty)
Number of subjects: 30

Group type: COMPARATOR
Intervention: TAP group compared to non-TAP group
Number of subjects: 30
Study: 7910028

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg once daily
Number of subjects: 325

Group type: COMPARATOR
Intervention: Atenolol 50 mg once daily
Number of subjects: 325
Study: 3389397

Group type: EXPERIMENTAL
Intervention: Low Calorie (LC) diet - 40% fewer calories than MC
Number of subjects: 48

Group type: COMPARATOR
Intervention: Medium Calorie (MC) diet
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High Calorie (HC) diet - 40% more calories than MC
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 48
Study: 31299040

Group type: EXPERIMENTAL
Intervention: Transfusion guidelines developed through a modified Delphi process
Number of subjects: 35
Study: 28985751

Group type: EXPERIMENTAL
Intervention: Kinesio tape
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham tape
Number of subjects: 22
Study: 24182645

Group type: EXPERIMENTAL
Intervention: internal fixation of two parallel reconstruction plates
Number of subjects: 57
Study: 22695506

Group type: EXPERIMENTAL
Intervention: Atenolol-based therapy
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Losartan-based therapy
Number of subjects: 801
Study: 20400271

Group type: EXPERIMENTAL
Intervention: Moxifloxacin monotherapy
Number of subjects: 3903
Study: 18074762

Group type: EXPERIMENTAL
Intervention: Test fixed dose combination of nitazoxanide 500 mg and ofloxacin 200 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference fixed dose combination of nitazoxanide 500 mg and ofloxacin 200 mg
Number of subjects: 24
Study: 15821687

Group type: EXPERIMENTAL
Intervention: 0.4% stannous fluoride gel (SFG) for 4 minutes
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (without 0.4% SFG)
Number of subjects: 47
Study: 12358958

Group type: EXPERIMENTAL
Intervention: NIRO 300
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: INVOS 5100
Number of subjects: 10

Group type: COMPARATOR
Intervention: Both monitors (NIRO 300 and INVOS 5100)
Number of subjects: 10
Study: 9972758

Group type: EXPERIMENTAL
Intervention: Epidural steroids administered with fluoroscopic guidance
Number of subjects: 50

Group type: COMPARATOR
Intervention: Epidural steroids administered without fluoroscopic guidance
Number of subjects: 50
Study: 7593780

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S‐adenosylmethionine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2332096

Group type: EXPERIMENTAL
Intervention: Pulsatile glucagon delivery (377 ng/min for 2 min followed by 11 min with no infusion)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Continuous glucagon delivery (58 ng/min)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Pulsatile glucagon delivery
Number of subjects: 7

Group type: COMPARATOR
Intervention: Continuous glucagon delivery
Number of subjects: 7
Study: 6996158

Group type: EXPERIMENTAL
Intervention: Combination of penicillins, probenecid, a sulphonamide and ornidazole (once-only administration)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Combination of penicillins, probenecid, a sulphonamide and metronidazole
Number of subjects: 60
Study: 31564585

Group type: COMPARATOR
Intervention: Medical intervention alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carotid angioplasty/stenting (CAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current optimal medical intervention
Number of subjects: 0
Study: 30788788

Group type: EXPERIMENTAL
Intervention: Single-Strand Assembly (SSA) methods for combinatorial pathway engineering; details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combinatorial multigene pathway assembly scheme based on SSA and Golden Gate Assembly; details on dosage and duration not available.
Number of subjects: 0
Study: 28705783

Group type: EXPERIMENTAL
Intervention: Biofeedback intervention
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (oral simethicone)
Number of subjects: 48
Study: 25880946

Group type: EXPERIMENTAL
Intervention: Accelerated hepatitis B vaccination schedule (0-1-2 months)
Number of subjects: 707

Group type: COMPARATOR
Intervention: Standard hepatitis B vaccination schedule (0-1-6 months)
Number of subjects: 707
Study: 23652196

Group type: EXPERIMENTAL
Intervention: Pressure patching with ofloxacin ointment (patch group, PG)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Therapeutic contact lens with ofloxacin eye drops (contact lens group, CLG)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ofloxacin ointment alone (ointment group, OG)
Number of subjects: 66
Study: 21333698

Group type: EXPERIMENTAL
Intervention: Insomniacs
Number of subjects: 16

Group type: COMPARATOR
Intervention: Good sleepers
Number of subjects: 16
Study: 19479644

Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 31
Study: 17602156

Group type: EXPERIMENTAL
Intervention: Sulodexide
Number of subjects: 0
Study: 16299544

Group type: COMPARATOR
Intervention: Hematopoietic stem cell transplantation (HSCT)
Number of subjects: 306
Study: 12716667

Group type: EXPERIMENTAL
Intervention: Large portion of an entrée
Number of subjects: 30

Group type: COMPARATOR
Intervention: Age-appropriate portion of an entrée
Number of subjects: 30
Study: 10569329

Group type: EXPERIMENTAL
Intervention: 40 mg pravastatin/day
Number of subjects: 5804

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 5804
Study: 8915127

Group type: EXPERIMENTAL
Intervention: Octreotide (100 micrograms subcutaneously every 8 hours for a maximum of six doses)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (standard treatment with intravenous fluid replacement and antibiotic treatment)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control
Number of subjects: 33
Study: 1861552

Group type: EXPERIMENTAL
Intervention: Adjuvant hormonal therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant therapy
Number of subjects: 0
Study: 6882062

Group type: EXPERIMENTAL
Intervention: Praziquantel, single oral dose of 30 mg kg‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Niridazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metrifonate
Number of subjects: 0
Study: 31084635

Group type: EXPERIMENTAL
Intervention: Dynamic Interpersonal Therapy (DIT), 16 sessions over approximately 5 months
Number of subjects: 147

Group type: COMPARATOR
Intervention: Low-Intensity Treatment (LIT), control intervention
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioural Therapy (CBT)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Dynamic Interpersonal Therapy (DIT)
Number of subjects: 147
Study: 31868699

Group type: EXPERIMENTAL
Intervention: Electromechanically-assisted gait training (EAGT) using the Hybrid Assistive Limb (HAL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 0
Study: 28179351

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus S-1 chemotherapy
Number of subjects: 38
Study: 24658148

Group type: EXPERIMENTAL
Intervention: Double-bundle technique with autograft (DB-AU)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Double-bundle technique with allograft (DB-AL)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Single-bundle technique with allograft (SB)
Number of subjects: 424
Study: 23783025

Group type: EXPERIMENTAL
Intervention: Fortified human milk (HM)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Preterm infant formula
Number of subjects: 38
Study: 21744314

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 466

Group type: COMPARATOR
Intervention: Control (no tirofiban)
Number of subjects: 466
Study: 19491035

Group type: EXPERIMENTAL
Intervention: Biorelevant dissolution tests under simulated pre- and postprandial conditions
Number of subjects: 16

Group type: COMPARATOR
Intervention: Compendial dissolution tests using USP Apparatus 1 and 2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: In vivo administration of diclofenac sodium pellets
Number of subjects: 16
Study: 16307008

Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg + Tadalafil 20 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg + Sildenafil 100 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Tadalafil 20 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sildenafil 100 mg
Number of subjects: 24
Study: 15315647

Group type: EXPERIMENTAL
Intervention: AmF/SnF2 toothpaste + AmF/SnF2 mouthrinse
Number of subjects: 42

Group type: COMPARATOR
Intervention: AmF/SnF2 toothpaste only
Number of subjects: 42
Study: 10903223

Group type: EXPERIMENTAL
Intervention: Regular use of albuterol
Number of subjects: 190

Group type: COMPARATOR
Intervention: As-needed use of albuterol
Number of subjects: 190
Study: 9068463

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg for 4 weeks followed by either lansoprazole 30 mg or 60 mg for another 4 weeks
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 159

Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.i.d. for 8 weeks
Number of subjects: 159

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 159
Study: 8438610

Group type: EXPERIMENTAL
Intervention: Oral immunization with cholera toxin B-subunit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naive volunteers before immunization
Number of subjects: 0
Study: 3101242

Group type: EXPERIMENTAL
Intervention: Iron dextran (3 ml intramuscular iron dextran)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iron dextran
Number of subjects: 0
Study: 30049223

Group type: EXPERIMENTAL
Intervention: 35 mg of inhaled vaporized cannabis (18.2% Δ9‐tetrahydrocannabinol, <0.1% cannabidiol)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 35 mg of placebo control cannabis (CTRL; 0.33% Δ9‐tetrahydrocannabinol, <0.99% cannabidiol)
Number of subjects: 16
Study: 27684609

Group type: EXPERIMENTAL
Intervention: Body scan meditation
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 53
Study: 25662353

Group type: EXPERIMENTAL
Intervention: Fingolimod
Number of subjects: 992